Cognizant Total Cost of Revenue increased by 2.9% to $3.64B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.1%, from $3.40B to $3.64B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 4.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.86B | $2.95B | $3.03B | $3.10B | $3.12B | $3.08B | $3.15B | $3.14B | $3.23B | $3.21B | $3.08B | $3.15B | $3.20B | $3.31B | $3.30B | $3.40B | $3.48B | $3.58B | $3.53B | $3.64B |
| QoQ Change | — | +2.9% | +2.8% | +2.2% | +0.7% | -1.3% | +2.3% | -0.3% | +2.8% | -0.7% | -4.0% | +2.1% | +1.8% | +3.3% | -0.4% | +3.0% | +2.4% | +2.9% | -1.3% | +2.9% |
| YoY Change | — | — | — | — | +8.9% | +4.5% | +4.0% | +1.5% | +3.6% | +4.2% | -2.3% | +0.1% | -0.8% | +3.2% | +7.0% | +8.0% | +8.6% | +8.2% | +7.2% | +7.1% |